The Clinical Impact of the Novel Alzheimer's Blood-based Biomarkers

Enrolling by invitationOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

February 7, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

December 31, 2025

Conditions
Alzheimer DiseaseCognitive ImpairmentDementiaNeurodegenerative DiseasesFrontotemporal DementiaLewy Body DiseaseVascular Dementia
Interventions
DIAGNOSTIC_TEST

Early adoption of blood-based biomarkers for Alzheimer's disease

A blood test will be performed to obtain plasma measures of Amyloid-β (Aβ) 42/40, phosphorylated tau (p-tau) 181, p-tau217, p-tau231 and Glial fibrillary acidic protein (GFAP) and Neurofilament light chain (NfL) and results will be disclosure to the early and late arms at different time points.

Trial Locations (1)

08003

Hospital del Mar, Barcelona

All Listed Sponsors
lead

Hospital del Mar Research Institute (IMIM)

OTHER